Search

DG051

DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

Calcimycin

It binds to and transports calcium and other divalent cations across membranes, disrupts oxidative phosphorylation, and inhibits ATPase in rat liver mitochondria. … Primarily used as a biochemical tool for studying divalent cations in biological systems, Calcimycin also exhibits antibiotic activity against gram-positive bacteria and fungi.

Deserpidine

Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure

Apocynin

Acetovanillone has been used in trials studying the treatment of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.

CMLVAX100

CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. … It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.

Theofibrate

Theofibrate is a small molecule drug. The usage of the INN stem '-fylline' in the name indicates that Theofibrate is a N-methylated xanthine derivative. … The usage of the INN stem '-fibrate' in the name indicates that Theofibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.

VIT-100

It is believed that similar effects would be seen in cells isolated from hypertrophic scars. … In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control.

Zosuquidar

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.

Nitroxoline

Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. … It is a hydroxyquinoline derivative unrelated to other classes of drugs.[A179251] Nitroxoline is active against bacterial gyrases.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen